ObsEva Announces Corporate Updates

Rhea-AI Summary

ObsEva SA (NASDAQ: OBSV; SIX: OBSN) has announced the immediate resignation of Fabien de Ladonchamps from its Executive Committee, although he will continue as a senior management member. The biopharmaceutical company focuses on developing therapies for women’s reproductive health and pregnancy, particularly targeting preterm labor and improving live birth rates following IVF.

ObsEva emphasizes its commitment to drug development through strategic partnerships and has a pipeline that includes ongoing clinical trials and strategic collaborations.

Positive

• Key management continuity with Fabien de Ladonchamps remaining in senior management.
• Focus on women's health with established clinical pipeline targeting preterm labor and IVF outcomes.

Negative

• None.

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s health, today announced that Fabien de Ladonchamps, Chief Administrative Officer, is stepping down from the Company’s Executive Committee, effective immediately. Fabien de Ladonchamps will remain a member of senior management.

About ObsEva

ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical pipeline with development programs focused on new therapies for the treatment of preterm labor and improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “might”, “ongoing”, “objective”, “plan”, “potential”, “predict”, “should”, “will”, “would”, or the negative of these and similar expressions, and are based on ObsEva’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties in the outcome and potential impact of the Company’s filing for a court-sanctioned moratorium, including with respect to ObsEva’s agreements with third parties, in ObsEva’s ability to successfully restructure its operations and refocus the Company’s development and commercialization strategy, and to cooperate with Kissei or other third parties on the completion of the linzagolix extension studies, in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, including interactions with the FDA during the New Drug Application process for linzagolix, ObsEva’s reliance on third parties over which it may not always have full control, and the capabilities of such third parties, the impact of the ongoing novel coronavirus outbreak and other geopolitical events, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with Securities and Exchange Commission (SEC) on March 10, 2022, in the Report on Form 6-K filed with the SEC on May 17, 2022 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and, except as required by law, ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Administrative Contact
Shauna Dillon
shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Katja Buhrer
katja.buhrer@obseva.com
+1 (917) 969-3438

Attachment

• ObsEva ExCom Transition_27Jul2022_pdf

FAQ

What recent announcement did ObsEva make on July 27, 2022?

ObsEva announced that Fabien de Ladonchamps stepped down from the Executive Committee effective immediately but will remain a member of senior management.

What is ObsEva's focus in the biopharmaceutical sector?

ObsEva focuses on developing novel therapies for women's reproductive health and pregnancy, specifically addressing preterm labor and enhancing IVF success rates.

What are the ticker symbols for ObsEva?

ObsEva is traded under the ticker symbol 'OBSV' on Nasdaq and 'OBSN' on the SIX Swiss Exchange.

How is ObsEva managing its drug development efforts?

ObsEva is pursuing strategic in-licensing and disciplined drug development to enhance its clinical pipeline.